Galapagos NV Release: GSK2586184 Met Primary Endpoint In Phase 2a Psoriasis Study

Mechelen, Belgium, April 17, 2014 (GLOBE NEWSWIRE) -- Mechelen, Belgium; 17 April 2014 - Galapagos NV (Euronext: GLPG) announced today that GSK provided Galapagos with the following information:

"Study JAK116679 was a phase 2a multi-centre, randomised, double-blind, placebo-controlled, dose ranging study (100mg bid, 200mg bid, 400mg bid) that evaluated the safety and efficacy of GSK2586184 compared with placebo in 66 patients with chronic plaque psoriasis. Preliminary results showed that a significantly higher proportion of patients treated with GSK2586184 at the 400mg bid dose met the primary endpoint compared to placebo. The primary endpoint was defined as achieving >=75% improvement from baseline in Psoriasis Area Severity Index (PASI75) score at Week 12. PASI75 for patients randomised to placebo was in the range expected.

Help employers find you! Check out all the jobs and post your resume.